Connect Biopharma Holdings Limited (CNTB) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Connect Biopharma Holdings Limited (CNTB) Earnings Overview
As of June 22, 2026, Connect Biopharma Holdings Limited (CNTB) reported trailing twelve-month net income of -$22M, reflecting -257.1% year-over-year growth. The company earned $-0.40 per diluted share over the past four quarters, with a net profit margin of -86687.5%.
Looking at the long-term picture, CNTB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2024.
Connect Biopharma Holdings Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ABBV ($4.23B net income, 6.9% margin), REGN ($4.42B net income, 31.4% margin), ARQT (-$2M net income, -4.3% margin), CNTB has room to improve margins relative to the peer group. Compare CNTB vs ABBV →
CNTB Earnings vs Peers
Earnings metrics vs comparable public companies
CNTB Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$55M | -255.0% | -$58M | $-1.00 | -86687.5% | -90740.6% |
| 2024 | -$16M | +74.8% | -$22M | $-0.28 | -60.0% | -86.2% |
| 2023 | -$62M | +47.4% | -$69M | $-1.08 | - | - |
| 2022 | -$118M | +41.6% | -$119M | $-14.50 | - | - |
| 2021 | -$202M | -69.4% | -$98M | $-25.00 | - | - |
| 2020 | -$119M | -387.9% | -$30M | $-14.45 | - | - |
| 2019 | -$24M | - | -$16M | $-3.02 | - | - |
Download Data
Export CNTB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CNTB — Frequently Asked Questions
Quick answers to the most common questions about buying CNTB stock.
What is CNTB earnings per share (EPS)?
CNTB trailing twelve-month (TTM) diluted EPS is $-0.40, reflecting -257.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Connect Biopharma Holdings Limited's net income?
Connect Biopharma Holdings Limited (CNTB) trailing twelve-month net income is $-22M as of 2025. Earnings declined -257.1% year-over-year.
Is CNTB profitable?
CNTB is not currently profitable on a TTM basis, reporting a net loss of $-22M. Net margin is -86687.5%. Investors should monitor for a return to profitability.
What is CNTB's earnings growth rate?
CNTB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are CNTB's profit margins?
Connect Biopharma Holdings Limited net profit margin is -86687.5%, operating margin is -90740.6%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -82.7%.
Is CNTB growing earnings?
CNTB earnings are declining — EPS fell -257.1% year-over-year. TTM net income dropped to $-22M. This contrasts with the 5-year CAGR of N/A.
What was CNTB's best earnings year?
Connect Biopharma Holdings Limited's highest annual net income on record is $-16M, achieved in fiscal year 2024. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were CNTB's earnings last quarter?
CNTB's most recent reported quarter was Q4 2025. Net income was $-15M with diluted EPS of $-0.27. For a full breakdown of all quarters, see the quarterly earnings table on this page.